Teva reports FY 2021 revenue down 5% to $15.9B; GAAP EPS $0.38; Q4 GAAP loss

TEVA PHARMACEUTICAL INDUSTRIES LTD

2021-FY EPS reported $0.38 revenue$15,878,000,000

FY 2021 revenues $15.9B, down 5% YoY; GAAP diluted EPS $0.38 vs -$3.64 in 2020.
Q4 2021 GAAP diluted EPS $(0.14); Non-GAAP diluted EPS $0.77.
FY 2021 non-GAAP diluted EPS $2.58 (flat YoY); free cash flow $2.2B.
2022 outlook: revenue $15.6-$16.2B, non-GAAP EPS $2.40-$2.60, FCF $1.9-$2.2B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.